Easing trepidation about biologies

Kapes, Beth
September 2004
Dermatology Times;Sep2004 Supplement, Vol. 25, pS27
Trade Publication
Discusses the benefits offered by biologics for psoriasis treatment. Affirmation of David E. Cohen that the new biologic products offer advantages over existing medications; Presentation of new biologics that are approved for treating moderate to sever psoriasis and psoriatic arthritis; Discussion on the safety monitoring of new biologics.


Related Articles

  • Biologies for psoriasis pulling their weight. Wilson, Fred // Dermatology Times;Sep2004 Supplement, Vol. 25, pS18 

    The article discusses the effect of biologic therapy on psoriatic patients. Consideration of Amevive as the first biologic drug approved for moderate to severe plaque psoriasis; Elaboration on the effects of the drug, Raptiva; Responses of patients to Remicade infusions.

  • New oral psoriasis agents show promise. Jesitus, John // Dermatology Times;Sep2004 Supplement, Vol. 25, pS13 

    Introduces different oral treatment for psoriasis. Side effects of the retinoid, an oral tazarotene; Acquisition of a new oral formulation of the drug BG-12 oral fumarate by Biogen; Discussion on the effects of oral pimecrolimus on psoriatic patients.

  • Biologies open new, long-term approaches to doctors; patients face economic challenges. Jesitus, John // Dermatology Times;Sep2004 Supplement, Vol. 25, pS44 

    Focuses on the biologic treatments for psoriasis. Analysis on the biologics that won approval for treating the disease; Information on other biologics that are still unapproved; Affirmation on the economic challenges faced by patients with the new drugs in the market.

  • Biologic modalities for psoriasis emerging at lightning speed. Schwanke, Jane // Dermatology Times;Sep2004 Supplement, Vol. 25, pS45 

    Discusses the emergence of biologic drugs for treating psoriasis. Issues related to cost and insurance coverage; Statement of Craig Leonardi, associate clinical professor of dermatology in St. Louis University, on the ability of the current systematic treatments to control the disease; Selection...

  • new drugs for psoriasis might be lifesavers. Steinmehl, Eric; Martin, Adam // Health (Time Inc. Health);Mar2004, Vol. 18 Issue 2, p68 

    Provides information on biologics, a drug for treating psoriasis. Annual cost of the treatment; Percentage of people with psoriasis who consider committing suicide; Description of psoriasis.

  • For optimal result, begin treating with biologic while tapering conventional systemic therapy. Hill, Suzette // Dermatology Times;Sep2004 Supplement, Vol. 25, pS17 

    Discusses the safety and efficacy of biologics as first-line treatment option for psoriatic patients. Changes made to the doses of conventional systematic therapies; Affirmation that biologics also present an option for incremental improvements in patients from traditional therapies; Explanation...

  • New biologic therapeutics for psoriasis management. Samalonis, Lisa B. // Dermatology Times;Sep2004 Supplement, Vol. 25, pS28 

    Introduces biological agents for the treatment of psoriasis in Canada. Actions of the agents used as safe and effective alternatives to traditional therapies; Clinical trials conducted by researchers to test the efficacy of the agents; Influence of the biologics on cell response.

  • Study shows leading drugs' effectiveness against psoriasis. Jesitus, John // Dermatology Times;Sep2004 Supplement, Vol. 25, pS34 

    The article discusses the effectiveness of leading drugs against psoriasis. Statement of Craig L. Leonardi, associate dermatologist of St. Louis University in Missouri, on the effectiveness of Biogen's alefacept; Clarifications on the length of effectiveness of some drugs; Discussion on the...

  • Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival. Costanzo, Antonio; Malara, Giovanna; Pelucchi, Claudio; Fatiga, Francesco; Barbera, Giovanna; Franchi, Andrea; Galeone, Carlotta // Dermatology (10188665);Jul2018, Vol. 234 Issue 1/2, p1 

    Psoriasis is a complex and chronic disease, and, in most cases, therapies are required during all patients' lifetime. The efficacy and safety profiles of biological therapies are well established, but their effectiveness is still open to discussion. We performed a systematic review to summarize...


Read the Article

Other Topics